Biogen Idec has announced that Chairman William D. Young will retire from the its board of directors and will be replaced by Stelios Papadopoulos. The latter is a former investment banker specializing…
Trey Thoelcke The equity team at Jefferies has pulled their best ideas for clients to review while the market is mired in a sell-off. These focus stocks to buy represent the best value the…
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
Frank Golhen, via Wikimedia CommonsMost of the firms that we cover on Wall Street have presented their high conviction stock picks for 2014. The analysts at Credit Suisse have taken a little…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, January 27, 2014. They include Cisco Systems, Lululemon Athletica, Nokia, Peabody Energy and Xerox.
Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the…
In a new research report, the investment strategy team at Credit Suisse is recommending investors look to move out of the deep value stocks that have been so successful and consider stocks…
As 2013 begins to wind down, 24/7 Wall St. has started to scan our coverage of Wall Street firms for ideas that have truly big upside for next year. After such an…
ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance up 73%. Given…
ThinkstockThe UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed significantly year to date, hedge…
courtesy of AOL, IncHeading into the fourth quarter of this year, investors who have been long the stock market are poised for the best gains since the market exploded off the lows…
ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated…
Jon OggInvestors and traders alike are looking for ideas and recommendations now that the government shutdown is here and with a debt ceiling debate ahead. Each morning 24/7 Wall St. reviews dozens…
Investors and traders are worried about an end to quantitative easing, yet stocks are rallying hard on fundamentals. This puts these same investors in a spot where they have to wonder which…
ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top companies…
